Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC
Status:
Recruiting
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The proposed study will evaluate the safety and feasibility of preoperative administration
nivolumab +/- ipilimumab in patients with high-risk resectable NSCLC, and will facilitate a
comprehensive exploratory characterization of the tumor immune milieu and circulating immune
cells and soluble factors in these patients. Data obtained in this study will provide
valuable information for planning further prospective clinical trials of anti-PD-1 and other
immunotherapies in NSCLC, both in the peri-operative and advanced disease setting.
Phase:
Phase 2
Details
Lead Sponsor:
Sidney Kimmel Comprehensive Cancer Center Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins